deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01573702

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Non Small Cell Lung Cancer
Interventions Erlotinib Stereotactic Radiosurgery
Updated 14 times since 2017 Last updated: Dec 17, 2020 Started: Dec 11, 2012 Primary completion: Mar 15, 2019 Completion: Mar 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 14 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Aug 2020 · 15 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Feb 2021 — Dec 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Global Development, Inc.
  • UNC Lineberger Comprehensive Cancer Center
Data source: UNC Lineberger Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations